Hwaseong, South Korea
Hwaseong, South Korea

Time filter

Source Type

A tenofovir disoproxil phosphate, and a pharmaceutical composition including tenofovir disoproxil phosphate or a pharmaceutically acceptable salt thereof, a non-metallic salt disintegrant, and a non-metallic salt lubricant are provided.


The present invention provides an amorphous solid dispersion comprising a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present invention also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.


The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.


The present invention provides a method for mass production of human coagulation factor VII derivatives, containing: a) constructing an expression vector, containing i) a nucleotide sequence of a dihydrofolate reductase promoter devoid of at least one CCGCCC repeat sequence from the GC-rich region thereof and a nucleotide sequence encoding a dihydrofolate reductase (DHFR) operably linked thereto, and ii) a nucleotide sequence of a cytomegalovirus (CMV) early gene promoter and a nucleotide sequence encoding a human coagulation factor VII derivative operably linked thereto; b) transfecting an animal cell line with the expression vector of step a); c) culturing the transfected animal cell line of step b) in the presence of a dihydrofolate reductase inhibitor to select a cell line capable of expressing the human coagulation factor VII derivative with high efficiency; and d) culturing the animal cell line selected from step c) by adding at least one selected from the group consisting of sodium butyrate, vitamin K, and a culture medium supplement. Employing a vector containing a DHFR promoter devoid of GC-rich repeat sequences, the present invention can express human coagulation factor VII derivates with high efficiency on a large scale, and thus can be useful for the preparation of therapeutic agents for hemophilia.


Patent
Hanmi Pharm. Co. | Date: 2016-04-13

The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.


Patent
Hanmi Pharm. Co. | Date: 2016-01-06

The present invention relates to an insulin analog that has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin, a conjugate prepared by linking the insulin analog and a carrier, a long-acting formulation including the conjugate, and a method for preparing the conjugate.


Patent
Hanmi Pharm. Co. | Date: 2016-01-06

Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.


Patent
Hanmi Pharm. Co. | Date: 2016-05-18

The present invention relates to a physiologically active polypeptide-immunoglobulin Fc fragment conjugate, which comprises a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment, a method for preparing the conjugate, a method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition comprising the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn.


Patent
Hanmi Pharm. Co. | Date: 2016-08-03

The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.


Patent
Hanmi Pharm. Co. | Date: 2016-11-30

The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

Loading Hanmi Pharm Co. collaborators
Loading Hanmi Pharm Co. collaborators